Zacks Research Has Positive Outlook for Cencora Q1 Earnings

Cencora, Inc. (NYSE:COR) – Investment analysts at Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for shares of Cencora in a research report issued to clients and investors on Wednesday, November 27th. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will post earnings per share of $3.42 for the quarter, up from their previous estimate of $3.28. The consensus estimate for Cencora’s current full-year earnings is $14.93 per share. Zacks Research also issued estimates for Cencora’s Q2 2025 earnings at $4.11 EPS, Q4 2025 earnings at $3.70 EPS, FY2025 earnings at $14.82 EPS, Q3 2026 earnings at $3.85 EPS, Q4 2026 earnings at $3.97 EPS, FY2026 earnings at $16.17 EPS and FY2027 earnings at $17.41 EPS.

COR has been the topic of a number of other reports. Barclays boosted their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Bank of America restated a “neutral” rating and issued a $245.00 target price (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Evercore ISI boosted their target price on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. UBS Group boosted their price target on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $271.20.

Cencora Stock Down 0.7 %

Shares of Cencora stock opened at $249.90 on Monday. The business’s fifty day moving average price is $235.35 and its two-hundred day moving average price is $232.80. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The company has a market capitalization of $49.24 billion, a P/E ratio of 33.28, a PEG ratio of 1.67 and a beta of 0.44. Cencora has a 1-year low of $195.83 and a 1-year high of $253.27.

Hedge Funds Weigh In On Cencora

Several hedge funds have recently modified their holdings of COR. B. Riley Wealth Advisors Inc. bought a new position in Cencora in the 1st quarter valued at $411,000. Cetera Advisors LLC bought a new stake in Cencora during the first quarter worth about $2,091,000. EverSource Wealth Advisors LLC bought a new stake in Cencora during the first quarter worth about $325,000. GAMMA Investing LLC boosted its stake in Cencora by 35.5% during the second quarter. GAMMA Investing LLC now owns 2,762 shares of the company’s stock worth $622,000 after acquiring an additional 723 shares in the last quarter. Finally, DNB Asset Management AS lifted its stake in shares of Cencora by 13.4% in the second quarter. DNB Asset Management AS now owns 29,007 shares of the company’s stock worth $6,535,000 after buying an additional 3,432 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 93,018 shares of company stock worth $22,478,942. Corporate insiders own 15.80% of the company’s stock.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.88%. Cencora’s dividend payout ratio is presently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.